A Phase 4 interventional study of adapalene gel, 0.3% and clindamycin/benzoyl peroxide gel in Acne Vulgaris, sponsored by Galderma R&D. Completed at 4 sites in United States. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-08-23.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.
Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 18th largest by enrollment, is one of 2 that started in 2007, is one of 16 in phase 4, and was the 4th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:
Centre for Human Drug Research, Netherlands · Sites in Netherlands
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 9 · Phase 4 16
First in 2005; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 117 across the 34 interventional studies. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 29th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2007, is one of 20 in phase 4, and was the 10th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing clindamycin in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.
Same as above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
adapalene gel, 0.3% Other Names: Differin® Gel, 0.3% Applied once daily at bedtime clindamycin/benzoyl peroxide gel Other Names: Duac® Gel Applied once daily in the morning
Drug: adapalene gel, 0.3% · Drug: clindamycin/benzoyl peroxide gel
Applied once daily at bedtime
Also known as: Differin® Gel, 0.3%
Drug pages: Clindamycin · Benzoyl Peroxide
Applied once daily in the morning
Also known as: Duac® Gel
Percent Change From Baseline in Total Lesion Counts
Time frame: 6 and 12 weeks
Global Severity Assessment Success
Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear
Time frame: 6 and 12 weeks
Global Assessment of Improvement From Baseline
Time frame: 12 weeks
Worst Post Baseline Tolerability Assessment - Erythema
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
Time frame: 12 weeks
Worst Post Baseline Tolerability Assessment - Scaling
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
Time frame: 12 weeks
Worst Post Baseline Tolerability Assessment - Dryness
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
Time frame: 12 weeks
Worst Post Baseline Tolerability Assessment - Burning/Stinging
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
Time frame: 12 weeks
| Milestone | Combination Therapy |
|---|---|
| Started | 100 |
| Completed | 92 |
| Not completed | 8 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Lost to follow-up | 1 |
| Percent Change | Combination Therapy |
|---|---|
| Week 6 | -47 ± 24.43 |
| Week 12 | -64 ± 24.07 |
Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear
| participants | Combination Therapy |
|---|---|
| Week 6 | 8 |
| Week 12 | 42 |
| participants | Combination Therapy |
|---|---|
| Clear | 3 |
| Almost Clear | 40 |
| Marked Improvement | 27 |
| Moderate Improvement | 16 |
| Minimal Improvement | 5 |
| No Change | 8 |
| Worse | 1 |
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
| participants | Combination Therapy |
|---|---|
| None | 29 |
| Mild | 37 |
| Moderate | 33 |
| Severe | 0 |
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
| participants | Combination Therapy |
|---|---|
| None | 53 |
| Mild | 27 |
| Moderate | 16 |
| Severe | 3 |
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
| participants | Combination Therapy |
|---|---|
| None | 49 |
| Mild | 27 |
| Moderate | 20 |
| Severe | 3 |
Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
| participants | Combination Therapy |
|---|---|
| None | 67 |
| Mild | 18 |
| Moderate | 9 |
| Severe | 5 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Therapy | — | 0/99 (0%) | 32/99 (32.3%) |
| Event | Combination Therapy |
|---|---|
| Application Site BurnGeneral disorders | 32/99 |
| Application Site DrynessGeneral disorders | 24/99 |
| Application Site ErythemaGeneral disorders | 10/99 |
| Application Site ExfoliationGeneral disorders | 7/99 |
| Application Site DiscomfortGeneral disorders | 6/99 |
| Age, Continuous(years) | Combination Therapy |
|---|---|
| Mean | 18.2 ± 5.40 |
| Sex: Female, Male(Participants) | Combination Therapy |
|---|---|
| Female | 56 |
| Male | 44 |
| Race (NIH/OMB)(Participants) | Combination Therapy |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 10 |
| White | 77 |
| More than one race | 10 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Combination Therapy |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 93 |
| Unknown or Not Reported | 0 |
| Duration of Acne(years) | Combination Therapy |
|---|---|
| Mean | 4.0 ± 3.91 |
| Fitzpatrick Skin Type(participants) | Combination Therapy |
|---|---|
| I | 1 |
| II | 27 |
| III | 38 |
| IV | 22 |
| V | 4 |
| VI | 8 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Dec 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide